Evrysdi is the only non-invasive disease-modifying SMA treatment, with more than 18,000 people with SMA treated globally to date Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ...
The Scottish Medicines Consortium extends nusinersen access to pre-symptomatic 5q SMA infants after trial data showed most learned to walk.
Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, ...
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary muscle movement, according to the Muscular Dystrophy Association (MDA). It can ...
Significant unmet needs in SMA management include therapy access, fatigue, reproductive health, and emerging phenotypes in older patients. Intrathecal gene therapy offers potential for older SMA ...
All newborn babies in England will be tested for the genetic disease spinal muscular atrophy (SMA), as part of a major study. All newborn babies in England will be tested for the genetic disease ...
Join the 2026 Walk for Graham this Saturday at Grand Park to support spinal muscular atrophy research and celebrate local ...
Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, ...
As the feasibility of phase 1 clinical trials for prenatal spinal muscular atrophy (SMA) therapies is explored, patient and parent input on prenatal testing and possibly treatment is a valuable tool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results